Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Articles

Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

November 17th 2023

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC

June 2nd 2023

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Advanced NSCLC: Interpreting Data From the POSEIDON Trial

May 26th 2023

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations

May 26th 2023

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer

May 19th 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing

May 19th 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Factors in Selecting IO Therapy for Patients With Advanced NSCLC

May 12th 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Considerations for Incorporating Perioperative Treatment in Resectable NSCLC

May 12th 2023

Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.

Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer

May 5th 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?

May 5th 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Practical Advice on the Evolving Management of CSCC

May 3rd 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

April 28th 2023

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer

April 28th 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

CSCC: Escalating Therapy for High-risk Patients

April 26th 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Best Practices in Multidisciplinary Care for CSCC

April 26th 2023

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma

April 19th 2023

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

CSCC: Translating Cemiplimab Data Into Practice

April 19th 2023

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

April 12th 2023

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials

April 12th 2023

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

Clinical Experience With Neoadjuvant IO Therapy in Melanoma

April 5th 2023

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.